Kit Fuhrman
Overview
Explore the profile of Kit Fuhrman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zimmerman S, Fropf R, Kulasekara B, Griswold M, Appelbe O, Bahrami A, et al.
Genome Res
. 2022 Sep;
32(10):1892-1905.
PMID: 36100434
Emerging spatial profiling technology has enabled high-plex molecular profiling in biological tissues, preserving the spatial and morphological context of gene expression. Here, we describe expanding the chemistry for the Digital...
2.
Hwang W, Jagadeesh K, Guo J, Hoffman H, Yadollahpour P, Reeves J, et al.
Nat Genet
. 2022 Jul;
54(8):1178-1191.
PMID: 35902743
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet inform clinical management or therapeutic development. Here, we...
3.
Zugazagoitia J, Gupta S, Liu Y, Fuhrman K, Gettinger S, Herbst R, et al.
Clin Cancer Res
. 2020 Apr;
26(16):4360-4368.
PMID: 32253229
Purpose: Only a minority of patients with advanced non-small cell lung cancer (NSCLC) truly benefits from single-agent PD-1 checkpoint blockade, and more robust predictive biomarkers are needed. Experimental Design: We...
4.
Gupta S, Zugazagoitia J, Martinez-Morilla S, Fuhrman K, Rimm D
Lab Invest
. 2020 Apr;
100(10):1311-1317.
PMID: 32249818
The assessment of programmed death 1 ligand 1 (PD-L1) expression by Immunohistochemistry (IHC) is the US Food and Drug Administration (FDA)-approved predictive marker to select responders to checkpoint blockade anti-PD-1/PD-L1...
5.
Wong W, Baltay M, Getz A, Fuhrman K, Aster J, Hasserjian R, et al.
PLoS One
. 2019 May;
14(5):e0216810.
PMID: 31071164
The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) share similar molecular characteristics in that they frequently harbor hotspot mutations in JAK2, CALR or MPL, leading to activated JAK/STAT signaling. However, these MPN...
6.
Tolaney S, Guo H, Pernas S, Barry W, Dillon D, Ritterhouse L, et al.
J Clin Oncol
. 2019 Apr;
37(22):1868-1875.
PMID: 30939096
Purpose: The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The primary analysis of the...